X
Jan 11, 2022 12:19 PM (GMT+8) · EqualOcean
According to Article 83 of the drug administration law of the people's Republic of China and other relevant provisions, the State Drug Administration organized the post marketing evaluation of Lianbizhi injection. After evaluation, the State Drug Administration decided to stop the production, sales and use of Lianbizhi injection in China from now on, and cancel the drug registration certificate. The holder of the drug marketing license shall be responsible for recalling the products that have been sold on the market. The recalled products shall be destroyed under the supervision of the local provincial drug regulatory department or other harmless treatment measures shall be taken according to law.

This text is a result of machine translation.